Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $29.9 million.

  • Ironwood Pharmaceuticals' Share-based Compensation fell 56.63% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year decrease of 47.06%. This contributed to the annual value of $29.9 million for FY2024, which is 6.73% down from last year.
  • Ironwood Pharmaceuticals' Share-based Compensation amounted to $29.9 million in FY2024, which was down 6.73% from $32.0 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Share-based Compensation registered a high of $32.0 million during FY2023, and its lowest value of $22.3 million during FY2021.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Share-based Compensation value was $29.9 million (recorded in 2024), while the average stood at $29.6 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Share-based Compensation decreased by 28.53% in 2021, and later increased by 21.39% in 2022.
  • Over the past 5 years, Ironwood Pharmaceuticals' Share-based Compensation (Yearly) stood at $31.2 million in 2020, then fell by 28.53% to $22.3 million in 2021, then increased by 21.39% to $27.0 million in 2022, then rose by 18.33% to $32.0 million in 2023, then dropped by 6.73% to $29.9 million in 2024.